International Journal of Retina and Vitreous · 2018 · 20 citations · 22 references
MedicinePharmaceuticsPharmacologyBiopharmaceuticsClinical PharmacologyDrug DeliveryAngiogenesisRegulatory PharmacologyBiomolecular Binding AffinityEnzyme-linked Immunosorbent Assay (Elisa)Sterility TestingVascular Endothelial Growth FactorVascular Endothelial Growth Factor InhibitionVascular Endothelial Growth Factor InhibitorsVascular Endothelial Growth Factor ReceptorsVegfr Inhibitors
PURPOSE: To investigate the binding affinity, stability, and sterility of aflibercept and ziv-aflibercept to vascular endothelial growth factor (Holash et al. in Proc Natl Acad Sci USA 99(17):11393-11398, 2002. 10.1073/pnas.172398299) after compounding and storage for up to 28 days at 4 °C and - 8 °C. METHODS: Tuberculin-type 1-mL syringes were prepared containing aflibercept (40 mg/mL) and ziv-aflibercept (25 mg/mL). Samples were stored at 4 °C and - 8 °C for 0, 14, and 28 days and evaluated for the binding affinity of anti-VEGF to VEGF and stability using enzyme-linked immunosorbent assays. The evaluation of sample sterility was performed. RESULTS: Laboratory trials with aflibercept and ziv-aflibercept showed preservation of the drug-binding capability to recombinant VEGF when stored in plastic syringes for up to 28 days at 4 °C and - 8 °C. No significant decrease in mass or concentration were observed. Microbiologic evaluations did not detect contamination in the syringes. CONCLUSIONS: The current study corroborates that compounded anti-VEGF drugs aflibercept and ziv-aflibercept do not loose stability or binding affinity and do not become contaminated if prepared under sterile conditions and stored at 4 °C or - 8 °C for 14 or 28 days.
22
Ranibizumab for Neovascular Age-Related Macular Degeneration
Philip J. Rosenfeld, David M. Brown, Jeffrey S. Heier et al. · New England Journal of Medicine · 2006 · 5.9K citations · Full text
Medicine, Ophthalmology, Surgery +12
VEGF-Trap: A VEGF blocker with potent antitumor effects
Jocelyn Holash, Sam Davis, Susan D. Croll et al. · Proceedings of the National Academy of Sciences · 2002 · 1.7K citations
Medicine, Oncology, Pharmacology +17